Thirumalai Chemicals Limited shareholders approved the company’s audited financial statements for the financial year ended March 31, 2026, along with key governance resolutions at its 53rd Annual General Meeting. The meeting, held on August 07, 2026, via video conference, saw high participation from institutional investors and promoters, who overwhelmingly supported all five agenda items.

The proceedings were conducted in compliance with Section 108 of the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Remote e-voting was open from August 04, 2026, to August 06, 2026, with additional voting available during the meeting. M/s. R M Mimani & Associates LLP served as the scrutinizer for the voting process.

Key Resolutions Passed

Shareholders voted on five ordinary and special resolutions. The promoter group, holding 44,766,433 shares, participated with 99.59% of their stake. Public institutions held 11,196,678 shares, while non-institutional public shareholders held 64,589,663 shares.

Ms. Ramya Bharathram, Managing Director and CFO, retired by rotation and offered herself for reappointment, securing strong support from both promoter and public shareholders. The appointment of M/s. PKF Sridharan & Santhanam LLP as statutory auditor passed with 98.29% support, though it faced slightly higher opposition from public institutions compared to other resolutions.

Strategic Outlook and Operational Challenges

In his address, Chairman R. Parthasarathy outlined significant macroeconomic headwinds impacting the chemical sector over the past two years. He cited five major shocks: the Ukraine war, slowing Chinese consumption, post-pandemic supply chain inflation, recent US tariff hikes from near 3% to over 50%, and conflicts in Gaza and Iran driving up logistics and feedstock costs.

These disruptions forced the company to switch from nearly 100% domestic feedstock supply to 100% imports almost overnight. This shift impacted working capital needs and manufacturing stability for its liquid raw material requirements of 150,000–200,000 tons per year. Consequently, the company moved from a zero-debt position in 2021-23 to a high-debt scenario with elevated finance costs.

What the Numbers Show

Despite operational pressures, the company’s Gujarat subsidiary plant has stabilized, operating at 90–95% capacity utilization. The US project, though delayed by global events, is now complete with stage-wise startup in progress. The US subsidiary benefits from low butane prices compared to Asia and Europe, positioning it advantageously in the largest global market for food ingredients. Management indicated that the US subsidiary aims to become independent of India funding support by ramping up production in 2027 and 2028, thereby reducing group debt levels.

The Malaysian subsidiary has mothballed its front-end Maleic plant to reduce costs but continues operations in derivatives. Management emphasized that debt reduction remains a priority, supported by improved working capital management through better-structured credit lines from suppliers and bankers.

Thirumalai Chemicals reported a standalone net profit of ₹142 crore for the quarter ended June 30, 2026 (Q1FY27), marking a significant turnaround from the net loss of ₹138 crore recorded in Q1FY26. This recovery was driven by improved gross margins, which expanded to 35% from 16% year-on-year, supported by better business margins in Phthalic Anhydride (PAn) and cost-saving initiatives. In contrast, the consolidated entity recorded a net loss of ₹437 crore, primarily due to operational losses from its overseas subsidiary, TCL Specialties LLC, and higher finance costs associated with the ongoing construction of its manufacturing plant in the USA. The Group aims to commence the first phase of commercial operations at the new US facility by December 2026.

Financial Performance Overview

Standalone revenue from operations declined to ₹331 crore in Q1FY27 from ₹446 crore in the previous year’s quarter. Despite lower revenue, the standalone entity achieved an EBITDA of ₹51 crore, up significantly from ₹7 crore in Q1FY26. Gross profit rose to ₹118 crore from ₹71 crore, reflecting a margin expansion driven by market factors and small-scale cost-saving projects. Finance costs on a standalone basis increased to ₹24 crore from ₹16 crore. Basic and diluted earnings per share (EPS) stood at ₹1.2, recovering from a loss per share of ₹1.4 in Q1FY26.

The following table highlights key financial metrics:

Consolidated revenue rose to ₹547 crore from ₹450 crore in Q1FY26. However, consolidated finance costs surged to ₹52 crore from ₹18 crore, reflecting the capital expenditure burden associated with the US subsidiary’s manufacturing plant construction. The consolidated loss per share improved slightly to ₹3.6 from ₹5.9 in the prior year.

Liquidity and Fund Raising Strategy

The Group faces significant working capital challenges, with current liabilities exceeding current assets by ₹7,421 crore as of June 30, 2026. This gap is largely attributable to capital expenditure incurred by TCL Specialties LLC. The subsidiary is engaging with prospective lenders to raise debt funding of up to USD 130 to 180 million to support project completion and refinance existing borrowings. Financing is expected to be completed by October 2026.

At the standalone level, current liabilities exceed current assets by ₹3,253 crore, excluding loans receivable from subsidiaries amounting to ₹4,566 crore. The Board approved raising up to ₹750 crore through instruments including qualified institutions placement (QIP), preferential issue, further public offer, rights issue, or any permissible combination, subject to shareholder and regulatory approvals.

Operational Updates and Market Context

The PAn business performance was impacted by raw material shortages, particularly at the Dahej plant where working capital constraints affected procurement. However, the PAn reactor achieved 95% capacity utilization. The DGTR’s May 2026 sunset review recommended extending anti-dumping duties on Chinese and Korean imports for a further five years, providing some protection against structural pressure from Chinese overcapacity. Additionally, the India–EU Free Trade Agreement concluded in January 2026 will open zero-duty chemical access once implemented from 2027.

At Optimistic Organic Specialities Bhd (OOSB), Malaysia, focused operational optimization and cost-control measures supported a significant earnings improvement, resulting in positive EBITDA. The Board also approved the sale of four windmills with an installed capacity of 3.2 MW to TN Oxygen Private Limited for ₹10.35 crore to strengthen short-term liquidity.

What the Numbers Show

The divergence between standalone profitability and consolidated losses highlights the transitional phase of Thirumalai Chemicals’ global expansion strategy. While the core Indian operations are demonstrating robust margin recovery and operational efficiency—evidenced by the jump in standalone EBITDA margin from 2% to 15%—the consolidated bottom line remains weighed down by the capital-intensive US project. The significant rise in consolidated finance costs to ₹52 crore underscores the funding pressure during this construction phase. The upcoming commencement of commercial operations in December 2026 is critical for converting this capex burden into revenue-generating assets, potentially leveraging cost arbitrage between India and the US.